Optogenetic magnetic resonance imaging

Patent metadata

Field	Value
Publication number	US-10371776-B2
Application number	US-201815984115-A
Country	US
Kind code	B2
Filing date	May 18, 2018
Priority date	Nov 22, 2010
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

Disclosed herein are systems and methods involving the use of magnetic resonance imaging and optogenetic neural stimulation. Aspects of the disclosure include modifying a target neural cell population in a first region of a brain to express light-responsive molecules. Using a light pulse, the light-responsive molecules in the target neural cell population are stimulated. Multiple regions of the brain are scanned via magnetic resonance imaging. The scans allow for observation of a neural reaction in response to the stimulation in at least one of the multiple regions of the brain.

First claim

What is claimed is:

1. A system for carrying out functional magnetic resonance imaging (fMRI) in an individual, the system comprising:
a) an apparatus for delivering a nucleic acid comprising:
i) a nucleotide sequence encoding a first light-responsive opsin polypeptide to a first target neural cell population in a first region of a brain of the individual to produce a first modified target cell population in the first region of the brain, and
ii) a nucleotide sequence encoding a second light-responsive opsin polypeptide to a second target neural cell population in a second region of a brain of the individual to produce a second modified target cell population in the second region of the brain;

b) a light source for delivering:
i) a first light pulse to the second region of the brain, thereby stimulating the second region of the brain, and
ii) a second light pulse to the first region of the brain, thereby stimulating the first region of the brain; and

c) a functional magnetic resonance imaging (fMRI) device that is configured to scan multiple regions of the brain to:
i) allow for observation of a first neural reaction in response to the first light pulse in at least one of the multiple regions of the brain and, in response, determine whether neural projections in the second region of the brain are connected to at least some of the first modified target cell population in the first region of the brain, and
ii) allow for observation of a second neural reaction in response to the second light pulse in at least one of the multiple regions of the brain and, in response, determine whether neural projections in the first region of the brain are connected to at least some of the second modified target cell population in the second region of the brain.

2. The system of claim 1 , wherein the first light pulse emits light at a different wavelength than the wavelength of the second light pulse.

3. The system of claim 1 , wherein the apparatus for delivering the nucleic acid comprises a cannula.

4. The system of claim 1 , wherein the nucleotide sequence encoding the first light-responsive opsin is operably linked to a first cell type-specific promoter and the nucleotide sequence encoding the second light-responsive opsin is operably linked to a second cell type-specific promoter.

5. The system of claim 1 , wherein the first light-responsive opsin polypeptide is a channelrhodopsin-2 polypeptide derived from Chlamydomonas rheinhardtii , a channelrhodopsin polypeptide derived from Volvox carteri , a step function opsin (SFO), or an optoXR.

6. The system of claim 1 , wherein the second light-responsive opsin polypeptide is a channelrhodopsin-2 polypeptide derived from Chlamydomonas rheinhardtii , a channelrhodopsin polypeptide derived from Volvox carteri , a step function opsin (SFO), or an optoXR.

7. The system of claim 1 , wherein the nucleic acid is a viral vector.

8. The system of claim 1 , wherein the first target neural cell population is in the motor cortex, the anterior thalamus, the posterior thalamus, or the somatosensory cortex.

9. The system of claim 1 , wherein the second target neural cell population is in the motor cortex, the anterior thalamus, the posterior thalamus, or the somatosensory cortex.

10. The system of claim 2 , wherein the first target neural cell population is the same as the second target neural cell population.

11. The system of claim 1 , wherein the light source is an optical fiber.

12. A method comprising:
a) modifying a first target neural cell population in a first region of a brain to express a first light-responsive opsin polypeptide;
b) modifying a second target neural cell population in a second region of the brain to express a second light-responsive opsin polypeptide, wherein the first target neural cell population and the second neural cell population are modified using an apparatus for delivering a nucleic acid comprising:
i) a nucleotide sequence encoding the first light-responsive opsin polypeptide, and
ii) a nucleotide sequence encoding the second light-responsive opsin polypeptide;

c) stimulating, using a light source, the first region of the brain and the second region of the brain, wherein the light source is configured to deliver:
i) a first light pulse to the second region of the brain, thereby stimulating the second region of the brain, and
ii) a second light pulse to the first region of the brain, thereby stimulating the first region of the brain; and

d) scanning multiple regions of the brain using a functional magnetic resonance imaging (fMRI) device that is configured to:
i) observe a first neural reaction in response to stimulation with the first light pulse in the second region of the brain and, in response, determine whether neural projections in the second region of the brain are connected to at least some of the first modified target cell population in the first region of the brain, and
ii) observe a second neural reaction in response to stimulation with the second light pulse in the first region of the brain and, in response, determine whether neural projections in the first region of the brain are connected to at least some of the second modified target cell population in the second region of the brain.

13. The method of claim 12 , wherein the first light pulse emits light at a different wavelength than the wavelength of the second light pulse.

14. The method of claim 12 , wherein the light source is configured to stimulate the first light-responsive opsin polypeptide or the second light-responsive opsin polypeptide at a first light pulse rate and a second light pulse rate.

15. The method of claim 12 , wherein the first region of the brain is in the motor cortex and the second region of the brain is the thalamus.

16. The method of claim 12 , wherein the observed first or second neural reactions are used to determine a treatment plan for a disease effecting at least one of the first or second regions of the brain.

17. The method of claim 12 , further comprising:
introducing a drug into the brain, and repeating the steps of stimulating the first region of the brain or the second region of the brain, and scanning multiple regions of the brain; and
determining the effectiveness of the drug based on a comparison of the observed first or second neural reactions in the scan before the introduction of the drugs and the observed first or second neural reactions in the scan after the introduction of the drug.

18. The method of claim 14 , wherein the results of the stimulating at the first light pulse rate and the second light pulse rate are combined, and the method comprises providing a functional map of the brain including at least the results of the stimulating at the first light pulse rate and the second light pulse rate.

19. The method of claim 12 , wherein the functional magnetic resonance imaging device is configured to observe a blood oxygenation level-dependent (BOLD) signal response, and wherein the method further comprises inferring a relationship between the BOLD response depicted in the fMRI scan results and the neural cell stimulation.

20. The system of claim 12 , wherein the first light-responsive opsin polypeptide and the second light-responsive opsin polypeptide are selected from the group consisting of: channelrhodopsin-2 polypeptide derived from Chlamydomonas rheinhardtii , a channelrhodopsin polypeptide derived from Volvox carteri , a step function opsin (SFO), and an optoXR.

Assignees

• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Lee Jin Hyung

Classifications

• G16H30/40

  for processing medical images, e.g. editing · CPC title

• A61N5/0622

  Optical stimulation for exciting neural tissue · CPC title

• G01R33/4808

  Multimodal MR, e.g. MR combined with positron emission tomography [PET], MR combined with ultrasound or MR combined with computed tomography [CT] · CPC title

• G16H30/20

  for handling medical images, e.g. DICOM, HL7 or PACS · CPC title

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title